These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 33158907)

  • 1. Early Treatment Response Assessment Using
    Ceccon G; Lohmann P; Werner JM; Tscherpel C; Dunkl V; Stoffels G; Rosen J; Rapp M; Sabel M; Herrlinger U; Schäfer N; Shah NJ; Fink GR; Langen KJ; Galldiks N
    J Nucl Med; 2021 Jul; 62(7):918-925. PubMed ID: 33158907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response assessment of bevacizumab in patients with recurrent malignant glioma using [18F]Fluoroethyl-L-tyrosine PET in comparison to MRI.
    Galldiks N; Rapp M; Stoffels G; Fink GR; Shah NJ; Coenen HH; Sabel M; Langen KJ
    Eur J Nucl Med Mol Imaging; 2013 Jan; 40(1):22-33. PubMed ID: 23053325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early treatment response evaluation using FET PET compared to MRI in glioblastoma patients at first progression treated with bevacizumab plus lomustine.
    Galldiks N; Dunkl V; Ceccon G; Tscherpel C; Stoffels G; Law I; Henriksen OM; Muhic A; Poulsen HS; Steger J; Bauer EK; Lohmann P; Schmidt M; Shah NJ; Fink GR; Langen KJ
    Eur J Nucl Med Mol Imaging; 2018 Dec; 45(13):2377-2386. PubMed ID: 29982845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The diagnostic accuracy of detecting malignant transformation of low-grade glioma using O-(2-[18F]fluoroethyl)-l-tyrosine positron emission tomography: a retrospective study.
    Bashir A; Brennum J; Broholm H; Law I
    J Neurosurg; 2018 Apr; 130(2):451-464. PubMed ID: 29624154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. O-(2-18F-fluoroethyl)-L-tyrosine PET predicts failure of antiangiogenic treatment in patients with recurrent high-grade glioma.
    Hutterer M; Nowosielski M; Putzer D; Waitz D; Tinkhauser G; Kostron H; Muigg A; Virgolini IJ; Staffen W; Trinka E; Gotwald T; Jacobs AH; Stockhammer G
    J Nucl Med; 2011 Jun; 52(6):856-64. PubMed ID: 21622893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of pre-irradiation FET PET in patients with not completely resectable IDH-wildtype glioma and minimal or absent contrast enhancement.
    Rosen J; Stoffels G; Lohmann P; Bauer EK; Werner JM; Wollring M; Rapp M; Felsberg J; Kocher M; Fink GR; Langen KJ; Galldiks N
    Sci Rep; 2021 Oct; 11(1):20828. PubMed ID: 34675225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of response to lomustine-based chemotherapy in glioma patients at recurrence using MRI and FET PET.
    Wollring MM; Werner JM; Bauer EK; Tscherpel C; Ceccon GS; Lohmann P; Stoffels G; Kabbasch C; Goldbrunner R; Fink GR; Langen KJ; Galldiks N
    Neuro Oncol; 2023 May; 25(5):984-994. PubMed ID: 36215231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of treatment response in patients with glioblastoma using O-(2-18F-fluoroethyl)-L-tyrosine PET in comparison to MRI.
    Galldiks N; Langen KJ; Holy R; Pinkawa M; Stoffels G; Nolte KW; Kaiser HJ; Filss CP; Fink GR; Coenen HH; Eble MJ; Piroth MD
    J Nucl Med; 2012 Jul; 53(7):1048-57. PubMed ID: 22645298
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Suchorska B; Unterrainer M; Biczok A; Sosnova M; Forbrig R; Bartenstein P; Tonn JC; Albert NL; Kreth FW
    J Neurooncol; 2018 Sep; 139(3):721-730. PubMed ID: 29948765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of survival in patients with IDH-wildtype astrocytic gliomas using dynamic O-(2-[
    Bauer EK; Stoffels G; Blau T; Reifenberger G; Felsberg J; Werner JM; Lohmann P; Rosen J; Ceccon G; Tscherpel C; Rapp M; Sabel M; Filss CP; Shah NJ; Neumaier B; Fink GR; Langen KJ; Galldiks N
    Eur J Nucl Med Mol Imaging; 2020 Jun; 47(6):1486-1495. PubMed ID: 32034446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnosis of Pseudoprogression Following Lomustine-Temozolomide Chemoradiation in Newly Diagnosed Glioblastoma Patients Using FET-PET.
    Werner JM; Weller J; Ceccon G; Schaub C; Tscherpel C; Lohmann P; Bauer EK; Schäfer N; Stoffels G; Baues C; Celik E; Marnitz S; Kabbasch C; Gielen GH; Fink GR; Langen KJ; Herrlinger U; Galldiks N
    Clin Cancer Res; 2021 Jul; 27(13):3704-3713. PubMed ID: 33947699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnosis of pseudoprogression in patients with glioblastoma using O-(2-[18F]fluoroethyl)-L-tyrosine PET.
    Galldiks N; Dunkl V; Stoffels G; Hutterer M; Rapp M; Sabel M; Reifenberger G; Kebir S; Dorn F; Blau T; Herrlinger U; Hau P; Ruge MI; Kocher M; Goldbrunner R; Fink GR; Drzezga A; Schmidt M; Langen KJ
    Eur J Nucl Med Mol Imaging; 2015 Apr; 42(5):685-95. PubMed ID: 25411133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of O-(2-18F-fluoroethyl)-L-tyrosine PET as a diagnostic tool for detection of malignant progression in patients with low-grade glioma.
    Galldiks N; Stoffels G; Ruge MI; Rapp M; Sabel M; Reifenberger G; Erdem Z; Shah NJ; Fink GR; Coenen HH; Langen KJ
    J Nucl Med; 2013 Dec; 54(12):2046-54. PubMed ID: 24159047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic impact of postoperative, pre-irradiation (18)F-fluoroethyl-l-tyrosine uptake in glioblastoma patients treated with radiochemotherapy.
    Piroth MD; Holy R; Pinkawa M; Stoffels G; Kaiser HJ; Galldiks N; Herzog H; Coenen HH; Eble MJ; Langen KJ
    Radiother Oncol; 2011 May; 99(2):218-24. PubMed ID: 21497925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. O-(2-[(18)F]fluoroethyl)-L-tyrosine uptake is an independent prognostic determinant in patients with glioma referred for radiation therapy.
    Sweeney R; Polat B; Samnick S; Reiners C; Flentje M; Verburg FA
    Ann Nucl Med; 2014 Feb; 28(2):154-62. PubMed ID: 24272067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost Effectiveness of
    Rosen J; Ceccon G; Bauer EK; Werner JM; Tscherpel C; Dunkl V; Rapp M; Sabel M; Herrlinger U; Heinzel A; Schäfer N; Ruge M; Goldbrunner R; Stoffels G; Kabbasch C; Fink GR; Langen KJ; Galldiks N
    J Nucl Med; 2022 Nov; 63(11):1677-1682. PubMed ID: 35422443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
    Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
    Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differentiation of treatment-related changes from tumour progression: a direct comparison between dynamic FET PET and ADC values obtained from DWI MRI.
    Werner JM; Stoffels G; Lichtenstein T; Borggrefe J; Lohmann P; Ceccon G; Shah NJ; Fink GR; Langen KJ; Kabbasch C; Galldiks N
    Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1889-1901. PubMed ID: 31203420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glioma Recurrence Versus Radiation Necrosis: Single-Session Multiparametric Approach Using Simultaneous O-(2-18F-Fluoroethyl)-L-Tyrosine PET/MRI.
    Jena A; Taneja S; Gambhir A; Mishra AK; Dʼsouza MM; Verma SM; Hazari PP; Negi P; Jhadav GK; Sogani SK
    Clin Nucl Med; 2016 May; 41(5):e228-36. PubMed ID: 26859208
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Fleischmann DF; Unterrainer M; Bartenstein P; Belka C; Albert NL; Niyazi M
    J Neurooncol; 2017 Apr; 132(2):277-286. PubMed ID: 28102485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.